Recently, while preparing an updated presentation to the Saint Louis University cardiology fellows on "diastolic dysfunction," the Skeptical Cardiologist came across a document entitled "What Does ...
Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...
In a 4.3-year follow-up study, few asymptomatic patients with preclinical left ventricular diastolic dysfunction (LVDD) progressed to heart failure with preserved ejection fraction (HFpEF), with a ...
Researchers from Edgewise Therapeutics Inc. presented preclinical data for the cardiac sarcomere modulator, EDG-7500, which is being developed for the treatment of hypertrophic cardiomyopathy (HCM) ...
Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.
Orchestra BioMed Holdings, Inc. announced promising echocardiographic data regarding atrioventricular interval modulation (AVIM) therapy's impact on patients with diastolic dysfunction at the THT 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results